Login to Your Account

Upward-motility financing garners Neurogastrx $45M for gastroparesis work

By Randy Osborne
Staff Writer

Thursday, January 4, 2018

With $45 million in series A money, Neurogastrx Inc. has enough to pay for proof-of-concept work with NG-101, a peripherally restricted dopamine D2/D3 receptor antagonist for gastroparesis, an indication that involves delayed emptying of the stomach – and one that's proved tricky for drug developers.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription